Secarna Pharmaceuticals

📢 Secarna’s CSO to present at TIDES Europe 2024 Frank Jaschinski, Chief Scientific Officer of Secarna, will attend the TIDES: Oligonucleotides and Peptide Therapeutics Europe 2024 conference, presenting details on two of our lead programs in antisense therapeutics: First, our lead compound SECN-15, a locked nucleic acid (LNA)-modified #antisenseoligonucleotides targeting NRP1 expression, with the potential to overcome resistance to immune checkpoint inhibitors, both as monotherapy and in combination with anti-PD-1 #antibodies. Second, our ASOs targeting MLKL, a key player in the inflammatory cell death pathway known as “necroptosis” and a promising therapeutic target for conditions such as #acutekidneyinjury from ischemia reperfusion. Title: Antisense oligonucleotides for treatment of cancer and kidney diseases 🗓️ Presentation Date: Wednesday, November 13, 2024 🕒 Time: 9:05 – 9:35 AM, CET 📍 Location: Hamburg Congress Center, Hamburg, Germany Join us at TIDES Europe 2024 to learn more about our innovations in oligonucleotide technology and our commitment to tackling the high unmet medical needs in oncology and beyond. #Secarna #TIDESEurope #OligonucleotideTherapeutics #Innovation #CancerResearch #OligoCreator

🎤“Our claim to fame is really getting from undruggable to druggable,” said Konstantin Petropoulos, CEO of Secarna Pharmaceuticals in his Spotlight video filmed at #BioEurope2024, Europe’s leading partnering event for the biotechnology industry. Curious to know what else he had to say about our twofold #businessmodel, our AI-empowered OligoCreator platform, and why we are the partner of choice when it comes to oligonucleotide-based drug compounds? Then, have a look at his full interview with MC Services AG: https://lnkd.in/ePemZ7tj #InTheSpotlight #ExpertInsights #CEOInterview

📢 Secarna at the #SITC2024 Annual Meeting!   Richard Klar, Secarna Pharmaceuticals’ Chief Research Officer will attend the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), from November 6 - 10, 2024, in Houston, TX, USA. He will present a poster on our lead program SECN-15 which targets NRP1 expression using locked nucleic acid (LNA)-modified #antisenseoligonucleotides. The data shows strong anti-tumor efficacy in murine cancer models as monotherapy as well as in combination with anti-PD-1 #antibodies. This underlines the potential of SECN-15 to break resistance to immune checkpoint inhibitors.   Additionally, Richard will provide insights into currently ongoing in-depth mode of action and translational research studies that aim to prioritize cancer indications for the planned clinical Phase I/II trial.   Title: Downregulation of Neuropilin-1 expression with antisense oligonucleotides in combination with checkpoint inhibitors demonstrates remarkable anti-tumor activity in vivo Poster #: 738 📍: George R. Brown Convention Center, Level 1 - Exhibit Halls AB 🗓️: Saturday November 9, 2024 | 9:00 am - 8:30 pm   This event is a fantastic opportunity to connect with global leaders in immunotherapy and immuno-oncology and showcase our innovative approaches in targeting difficult-to-treat disorders.   If you’re attending SITC, be sure to stop by and chat with Richard! 👉 Learn more about the event here: https://lnkd.in/ggphnMEm   #Secarna #Networking #ImmunoOncology #OligonucleotideTherapeutics #OligoCreator

📢 Learn more about our AI-empowered OligoCreator platform on our brand-new website   We’re thrilled to introduce our proprietary, AI-empowered oligonucleotide discovery and development platform, OligoCreator. The platform combines both innovative and proven delivery modalities such as antibodies, peptides and carbohydrates with the precision and specificity of oligonucleotides. With OligoCreator, we identify and characterize oligonucleotide therapeutics with unparalleled speed and excellent safety and efficacy, revolutionizing treatments for a wide range of difficult-to-treat disorders.   At the same time, we are launching our brand-new website, featuring enriched content that reflects our commitment to transform untreatable conditions into treatable ones.   💻 Visit www.secarna.com to learn more about our work and explore how we’re pushing the boundaries of oligonucleotide therapy!   #OligoCreator #OligonucleotideTherapeutics #WebsiteLaunch #NewLogo 

📢 Leadership update at Secarna!   We’re happy to announce that Konstantin Petropoulos will step into the role of #ChiefExecutiveOfficer. Konstantin has served as Secarna Pharmaceuticals’ Chief Business Officer since June 2023.   “My enthusiasm has grown as I’ve seen our partnered programs advance into the clinic and as we produce highly differentiated proprietary preclinical projects. I very much look forward to leading Secarna in its next stage, as we deliver best-in-class oligonucleotide therapeutics that offer the possibility of transforming untreatable conditions into treatable ones and profoundly changing the future of medicine”, he stated.   Alexander Gebauer is stepping down with immediate effect to focus on his work at Galimedix Therapeutics, Inc., where he is co-founder and executive chairman. He will continue to serve as strategic advisor to Secarna. We extend our deepest gratitude to Alexander for his #leadership, dedication, and contributions to Secarna’s growth. Join us in congratulating Konstantin on his new role leading Secarna in its next stage, where we continue to grow our business and advance our pipeline. 👏   #LeadershipChange #LeadershipMatters #BIOEurope

🌍 Secarna at BIO-Europe 2024 in Stockholm! Konstantin Petropoulos and Dr. Shilpashree Mallesh will attend #BIOEurope, Europe’s premier life sciences partnering event! With the continued growth and success of our #AI -empowered oligonucleotide discovery and development platform, we look forward to connecting with industry leaders to explore new collaboration opportunities and showcase our latest advancements in #oligonucleotidetherapeutics. If you’re attending BIO-Europe, don’t miss the chance to reach out via the partnering program and connect with us to discuss how our innovative solutions have the potential to transform untreatable conditions into treatable ones, changing the future of medicine together with you. Connect with us via the 1on1 partnering system 👉: https://lnkd.in/dMsTNtrX #BIOEurope #Innovation #Networking

🔊We are thrilled to share that Andre Maaske, Research Scientist at Secarna, will deliver the keynote presentation at the upcoming 2nd Annual MarketsandMarkets™ ImmunoBio Series conference in Freiburg, Germany, on October 15 at 9 am CET! 🧬 In his presentation entitled “Neuropilin-1 (NRP1) as novel target for antisense oligonucleotides (ASOs) to treat patients with solid tumors”, Andre will share insights into the latest advancements in antisense oligonucleotide therapeutics, specifically focusing on their application in the exciting field of immuno-oncology. With his expertise in next-generation ASO technologies, this is a presentation you won’t want to miss! 👉 More details on the event here: https://lnkd.in/e6jiU9bB #ImmunoBioSeries2024 #AntisenseTherapeutics #Innovation

🔊 Secarna CEO Alexander Gebauer, M.D., Ph.D. and CBO Konstantin Petropoulos, Ph.D., MBA, will attend #BioJapan in Yokohama, Japan, October 9-11, 2024. 🌏We are excited to attend the largest biotech partnering event in Asia for the first time. This incredible opportunity allows us to showcase our latest advancements in the discovery and development of best-in-class oligonucleotide therapeutics and to connect with thought leaders in biotechnology, pharmaceuticals and healthcare in Asia.   We look forward to seeing you.   #BiotechConferences #InnovationInHealthcare #Oligonucleotides

Meet us at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society in Montreal, Canada from October 6 - 9, 2024! Secarna’s Chief Scientific Officer, Frank Jaschinski, will present our latest work with MLKL-specific ASOs. MLKL plays a central role in an inflammatory cell death pathway termed “necroptosis” and has evolved as an attractive therapeutic target for the treatment of a wide range of diseases including acute kidney injury caused by ischemia reperfusion. Join us October 7 for our poster presentation P121 on “Targeting the necroptosis pathway by downregulating MLKL expression with antisense oligonucleotides”. Don’t miss the chance to stop and engage with Frank about how our innovative ASO therapies are addressing unmet medical needs! 👉 Learn more about the conference here: https://lnkd.in/gXsgtqD5 #ots24 #antisensetherapies #networking #KidneyDisease

This week’s 24th Annual Biotech in Europe Forum #Sachs_BEF was a success. Besides the opportunity to connect with investors, thought leaders and innovators from around the globe, our CBO Konstantin Petropoulos participated in the panel Platform Technologies & Novel Therapeutics: Diverse Business Models alongside with Joachim Vogt, Director Search & Evaluation International, AbbVie Inc., Kristian Tryggvason, Founder & CEO, Alder Therapeutics AB, Olav Zilian, MD, PhD, EMBA, Senior Financial Analyst, Pictet Group and Stephane Degove, CEO, Atamyo Therapeutics SAS. The panelists agreed that platforms – such as our oligonucleotide discovery platform – are helpful to grow biotech companies and generally trigger investor interests. For pharmaceutical companies, they are a valuable tool to create novel products for patients that urgently need them.